Memorial Sloan Kettering establishes MSKCC India

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Memorial Sloan Kettering Cancer Center has established MSKCC India to provide cancer patients in India with access to the institution’s oncologists, research, clinical trials, and education. 

MSKCC India will provide remote opinions via video or written consultations. A Memorial Sloan Kettering Cancer Center oncologist who specializes in a patient’s form of cancer will review their medical records, test results, and other materials and provide a comprehensive written opinion, meet with the patient virtually using telemedicine technology, or speak with the patient’s local oncologist about their diagnosis and care plan. 

In some cases, they may recommend that the patient travel to receive care at Memorial Sloan Kettering Cancer Center in New York City. Specific services include:

  • Pathology diagnosis
  • Radiology scan reviews
  • Next-generation sequencing (MSK-IMPACTTM) of a patient’s tumor and treatment recommendations
  • Travel assistance to New York City

Memorial Sloan Kettering Cancer Center has partnered with iCliniq, a global telemedicine provider based in India. 

MSKCC India will open a physical location in Chennai, centrally located for patients and staff members. This location will serve as a hub for medical staff who will help patients coordinate written or virtual consultations, and they will be able to communicate in English, Hindi, Urdu, Tamil, Telugu and Kannada. 

If necessary, employees will be able to collect medical records from patients’ homes, making the process more convenient for those utilizing this service. Patients across India will be able to obtain a remote opinion from experts at Memorial Sloan Kettering Cancer Center in the comfort of their home or any internet-enabled location without traveling to MSKCC India in Chennai.

Patients in India now can visit in.mskcc.org/india to learn more about MSKCC India and how to schedule a consultation with a Memorial Sloan Kettering Cancer Center expert.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login